The adoption of stereotactic body radiation therapy (SBRT) is associated with substantial improvements in overall and lung cancer-specific survival rates.
Human epidermal growth factor receptor 2 (HER-2) breast cancers are genetically heterogeneous.
Increase in the survival rate for elderly non-small cell lung cancer (NSCLC) attributed to increased use of stereotactic body radiation therapy (SBRT).
Encorafenib plus binimetinib significantly improved progression-free survival in melanoma.
Adding carfilzomib to melphalan and prednisone (KMP) is not superior to bortezomib, melphalan, prednisone (VMP) for improving progression-free survival.
Induction chemotherapy with concurrent chemoradiotherapy may improve survival of patients with nasopharyngeal cancer.
Patients with low-grade glioma have no significant difference in progression-free survival when treated with either radiotherapy alone or temozolomide chemotherapy alone.
Prostate-specific antigen (PSA) testing behavior did not significantly change in the years after a USPSTF recommendation against PSA screening.
Ibrutinib therapy carries a significantly higher risk of atrial fibrillation/flutter and all-grade bleeding compared with other treatments.
Magnetic resonance imaging (MRI) may be an effective tool for diagnosing hepatocellular carcinoma (HCC).
For patients with chronic myeloid leukemia, prolonged imatinib use helps achieve deeper molecular response with long-term treatment.
Nonwhite organ transplant recipients are at risk for developing non-melanoma skin cancer following transplantation.
TP53 and MDM2 alterations are associated with resistance to cisplatin and inferior progression-free survival among patients with metastatic germ cell tumors.
Alpha-fetoprotein (aFP) levels of at least 400 ng/mL predict patients with hepatocellular carcinoma (HCC) likely to respond to second-line ramucirumab.
Treatment with post-mastectomy radiotherapy (PMRT) reduces the risk for locoregional failure (LRF) recurrence and mortality.
The presence of circulating plasma cells (CPCs) predicts a worse prognosis for patients with multiple myeloma.
Response with low-dose ponatinib is similar to that of standard-dose ponatinib among patients with refractory chronic myeloid leukemia (CML).
Patients with chronic myeloid leukemia (CML) in accelerated phase may obtain less clinical benefit with first-line imatinib therapy.
Treatment with ibrutinib may be associated with favorable progression-free and overall survival as well as high overall response rate.
The FDA accepted a New Drug Application for neratinib for the extended treatment of patients with early HER2-positive breast cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Combined Treatment May Lead to Cure for Chronic Myeloid Leukemia
- Ghost and Honorary Authorship in Cancer Research
- Ibrutinib Linked With Favorable Survival, High Response Rate in CLL
- Risk of Arrhythmias, Bleeding Higher With Ibrutinib Therapy
- Emerging Prognostic Markers Continue to Improve Myeloma Treatment
- Use of SBRT Improves OS Rates Among Veterans With Stage I NSCLC
- Tumor-specific Biomarkers Predict Response in HER-2-positive Breast Cancer
- Survival Rate Rising Among Elderly Patients With NSCLC Treated With SBRT
- The Next Frontier: Radiotherapy Plus Immunotherapy for Melanoma Brain Metastases
- Encorafenib + Binimetinib Improves PFS Versus Vemurafenib Alone in Melanoma